Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Apr 24:2017:bcr2016218981.
doi: 10.1136/bcr-2016-218981.

Severe vincristine-induced polyneuropathy in a teenager with anaplastic medulloblastoma and undiagnosed Charcot-Marie-Tooth disease

Affiliations
Case Reports

Severe vincristine-induced polyneuropathy in a teenager with anaplastic medulloblastoma and undiagnosed Charcot-Marie-Tooth disease

Yasmin Aghajan et al. BMJ Case Rep. .

Abstract

Severe neuropathy is a known adverse effect of vincristine in patients with Charcot-Marie-Tooth disease (CMT). We present the case of a 16-year-old girl with anaplastic medulloblastoma treated with gross total resection and high-dose craniospinal radiation with adjuvant vincristine chemotherapy who developed acute-onset severe quadriplegia and vocal cord paralysis. Vincristine and radiation therapy were discontinued. Although her neuropathy slowly improved over several weeks, she developed metastatic extraneural medulloblastoma and died 5 months after diagnosis. Subsequent genetic testing revealed previously asymptomatic and undiagnosed CMT1A. Our case highlights the importance of early recognition of acute vincristine neurotoxicity that should raise suspicion of an underlying hereditary neuropathy.

Keywords: CNS cancer; Chemotherapy; Neurology; Neuromuscular disease; Neurooncology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Similar articles

Cited by

References

    1. Chauvenet AR, Shashi V, Selsky C, et al. . Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a pediatric oncology group study. J Pediatr Hematol Oncol 2003;25:316–20. 10.1097/00043426-200304000-00010 - DOI - PubMed
    1. Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol 2009;8:654–67. 10.1016/S1474-4422(09)70110-3 - DOI - PubMed
    1. Weimer LH, Podwall D. Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. J Neurol Sci 2006;242:47–54. 10.1016/j.jns.2005.11.014 - DOI - PubMed
    1. Ichikawa M, Suzuki D, Inamoto J, et al. . Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease. J Pediatr Hematol Oncol 2012;34:239–41. 10.1097/MPH.0b013e3182352cf5 - DOI - PubMed
    1. Nakamura T, Hashiguchi A, Suzuki S, et al. . Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation. Neurogenetics 2012;13:77–82. 10.1007/s10048-012-0313-1 - DOI - PubMed

Publication types

MeSH terms

Substances